HCR — Health Issues
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD
Lobbyists:
- ROBERT CLAYTON ALSPACH — covered position: Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
- JOSH TRENT — covered position: Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel
- mrs SHANNON ROHN DEERE
- NOOR AHMAD [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE